Unless data gathering for the Socio Economic and Caste Census is refined, the exercise could cast out the real claimants. Have the census enumerators recently knocked on your door with swanky tablet computers in hand? If they have, it's because they have begun to go door-to-door in most States to complete the final phase of the Socio Economic and Caste Census (SECC). This mammoth exercise is being coordinated by more than...

Under fire over data integrity issues, the government has tasked a panel to revise the wholesale price index (WPI) with the mandate to "enhance the reliability" of official statistics on all inflation measures.  The 31-member panel, to be headed by Planning Commission member Saumitra Chaudhuri, has also been asked to explore the possibility of getting a single agency to collect data for compiling WPI and industrial production that are hitherto dealt...

-Economic and Political Weekly The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines.   The German pharmaceutical company Bayer holds the patent...

India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...